Autologous (self) mononuclear cells derived from umbilical cord blood (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 211 | 左心低形成症候群 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03779711 (ClinicalTrials.gov) | December 12, 2018 | 4/12/2018 | Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome | Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2) | Hypoplastic Left Heart Syndrome | Biological: Autologous (self) mononuclear cells derived from umbilical cord blood;Procedure: Stage II Surgical repair | Timothy J Nelson, MD, PhD | University of Oklahoma;Children's Hospital of Philadelphia;Children's Hospital Los Angeles;Children's Hospital Colorado;Children's Hospitals and Clinics of Minnesota;Ochsner Health System;Children's of Alabama | Recruiting | N/A | 12 Months | All | 100 | Phase 2 | United States |